Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Co.'s proprietary technology utilizes Chimeric AutoAntibody Receptor, T cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Co.'s main CAAR T cell product candidate was designed based on the Chimeric Antigen Receptor, T cell technology that is marketed for the treatment of B cell cancers. Co.'s initial focus is mucosal pemphigus vulgaris, which is an autoimmune blistering disease. The CABA average annual return since 2019 is shown above.
The Average Annual Return on the CABA average annual return since 2019 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether CABA average annual return since 2019 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the CABA average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|